|Mr. Christopher J. Reinhard||Co-Founder, CEO, Pres, Treasurer, Sec. & Director||164.31k||N/A||1954|
|Mr. Duane Linstrom||Gen. Counsel||119.23k||N/A||N/A|
|Mr. James L. Grainer||Chairman, CFO & Sec.||N/A||N/A||1955|
|Dr. Lois A. Chandler||Chief Operating Officer||N/A||N/A||N/A|
|Dr. Ronald J. Shebuski||Chief Scientific Officer||N/A||N/A||N/A|
|Mr. Kelly D. Scott||VP of Bus. Devel. of Medtech Bus. Unit and EVP of Inner Cool Therapies Inc||N/A||N/A||1956|
Gene Biotherapeutics, Inc. manages a portfolio of medical technologies in the United States. It focuses on acquiring and developing gene-based therapeutics. The company, through its subsidiary, Angionetics, Inc., focuses on the clinical advancement and commercialization of Generx, an interventional cardiology, angiogenic gene therapy Phase 3 product candidate designed for the potential treatment of patients with refractory angina due to advanced coronary artery disease. It also holds royalties on the commercialization of Excellagen technology platform for advanced wound care in Eurasian countries. The company was formerly known as Taxus Cardium Pharmaceuticals Group, Inc. and changed its name to Gene Biotherapeutics, Inc. in January 2018. Gene Biotherapeutics, Inc. was founded in 2003 and is headquartered in San Diego, California.
Gene Biotherapeutics, Inc.’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.